Participants - All
Participant search result
Founder of Artman Technologies since 1991. First web based national transplant system. Implemented in more than 29 countries. www.artman.eu
Founder of Artman Technologies since 1991. First web based national transplant system. Implemented in more than 29 countries. www.artman.eu
Project Manager
Bratislava, Slovakia
I work at SARIO, a government agency that supports business growth and export activities of Slovak companies.
I work at SARIO, a government agency that supports business growth and export activities of Slovak companies.
I am CEO of Medic Labor, driving innovation in healthcare, biotech and digital solutions. We build partnerships and expand globally with secure technologies.
I am CEO of Medic Labor, driving innovation in healthcare, biotech and digital solutions. We build partnerships and expand globally with secure technologies.
I am the owner and representative of a Slovak IT company specialising in custom software development in AI, automation, cloud, data analytics and cybersecurity. I am open to international cooperation and innovation-driven projects.
I am the owner and representative of a Slovak IT company specialising in custom software development in AI, automation, cloud, data analytics and cybersecurity. I am open to international cooperation and innovation-driven projects.
I am driving international growth in IT and software development. I build strategic partnerships, lead complex client engagements, and turn business needs into scalable solutions that deliver long-term commercial value. We hear you and help.
I am driving international growth in IT and software development. I build strategic partnerships, lead complex client engagements, and turn business needs into scalable solutions that deliver long-term commercial value. We hear you and help.
I am CEO of Glycanostics, a company developing early-stage tests for detection of 11 types of cancer. The tests are based on detection of glycan changes in blood in ELISA format.
I am CEO of Glycanostics, a company developing early-stage tests for detection of 11 types of cancer. The tests are based on detection of glycan changes in blood in ELISA format.
I am the CEO of Selecta Biotech SE, a European joint-stock company founded with the ambition to implement a new generation of oligonucleotide therapeutics in clinical practice, with the aim of achieving the desired therapeutic effect without side effects.
I am the CEO of Selecta Biotech SE, a European joint-stock company founded with the ambition to implement a new generation of oligonucleotide therapeutics in clinical practice, with the aim of achieving the desired therapeutic effect without side effects.